



Salzburg
Cancer
Research
Institute

SALZBURG BREAST CANCER TALK 02. – 03.03.2018

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 2th MARCH

13:00 – 14:00 Come together and Lunch Buffet

14:00 Welcome and introduction

14:10 Current evidence of immunotherapy in breast cancer

Richard Greil (*Salzburg*)

Peter Schmid (*London*)

14:30–16:00 Immunogenicity I: Tumor - immune cell interaction

Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)

14:30 The role of B-cells and Tertiary Lymphoid structures (TLS)

Karen Willard-Gallo (*Brussels*)

14:50 The yin yang of innate immunity, inflammation and cancer

Alberto Mantovani (*Milan*)

15:10 Computing and probing cancer immunity

Zlatko Trajanoski (*Innsbruck*)

15:30 Panel discussion

16:00 – 16:30 Coffee break

16:30 – 18:00 Immunogenicity II: Triggers and Modulators

Chair: Fabrice André (Paris), Richard D. Kennedy (Belfast)

16:30 Influence on immunogenicity by driver mutations

Fabrice André (*Paris*)

16:50 Influence on immunogenicity by the microbioma

Maria Rescigno (*Milan*)

17:10 Influence on immunogenicity by DNA damage response deficiency

Richard D. Kennedy (*Belfast*)

17:30 Panel discussion

18:30 Dinner

SATURDAY, 3th MARCH

08:30 – 10:00 Monitoring and prediction of response to immunotherapy

Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)

08:30 Change of immune infiltrate during treatment*

Roberto Salgado (*Brussels*)

09:00 Monitoring anti-tumor immune response in the blood*

Alexander Egle (*Salzburg*)

09:30 Prediction of response to PD-1/PD-L1 blockade*

Marleen Kok (*Amsterdam*)

10:00 Neoantigene heterogeneity*

Marco Gerlinger (*London*)

10:30 – 11:00 Coffee break

11:00 – 12:30 Combination strategies with checkpoint-inhibitors

Chair: Richard Greil (Salzburg), Simon Gampenrieder (Salzburg)

11:00 Combination with chemotherapy

Giuseppe Curigliano (*Milan*)

11:20 Combination with vaccination

Richard Greil (*Salzburg*)

11:40 Combination with radiotherapy

Udo Gaipl (*Erlangen*)

12:00 Panel discussion

12:30 Lunch Buffet

* Discussion after lecture

The Pitter Event Center
Rainerstrasse 6 – 8
5020 Salzburg

www.imlauer.com



Free WLAN-Access:
CP event_open



Prof. Dr. Richard Greil
Head of the IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Peter Schmid FRCP MD PhD
Centre Lead | Centre for Experimental
Cancer Medicine
Director, Breast Cancer, St Bartholomew
Hospital London
London, United Kingdom

Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Prof. Alberto Mantovani MD
Humanitas University
Scientific Director
Istituto Clinico Humanitas IRCCS
Milan, Italy

Prof. Dipl.-Ing. Dr. Zlatko Trajanoski
Biocenter, Division for Bioinformatics
Medical University of Innsbruck
Innsbruck, Austria

Prof. Fabrice André MD PhD
Research Director, Head of INSERM
Unit U981
Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France

Prof. Maria Rescigno PhD
Director of Dendritic cell biology and
immunotherapy Unit
Director Immunotherapy programme,
European Institute of Oncology and
Dipartimento di Scienze della Salute,
Università di Milano
Milan, Italy

Prof. Richard Kennedy MD PhD
McClay Professor of Medical Oncology
Queen's University of Belfast
Global VP and Medical Director Almac
Diagnostics

Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research
Lab Department of Molecular Biology
University of Salzburg
Salzburg, Austria

Dr. Gabriel Rinnerthaler
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Dr. Roberto Salgado
Breast Cancer Translational Research
Laboratory, Department of Pathology, GZA
Institut Jules Bordet, Brussels
Antwerp, Belgium

Priv.-Doz. Dr. Alexander Egle
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Marleen Kok MD PhD
Research Fellow Cancer Immunotherapy
of the Dutch Cancer Society
The Netherlands Cancer Institute
Amsterdam, the Netherlands

Dr. Marco Gerlinger
Translational Oncogenomics Laboratory
Centre for Evolution and Cancer
Institute of Cancer Research
London, United Kingdom

Dr. Simon P. Gampenrieder
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Giuseppe Curigliano MD PhD
New Drugs and Early Drug Development
for Innovative Therapies Division
European Institute of Oncology
Milan, Italy

Prof. Dr. Udo Gaipl
Head of Radiation Immunobiology
Universitätsklinikum Erlangen
Department of Radiation Oncology
Erlangen, Germany

Organization:

Richard Greil
Gabriel Rinnerthaler
Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with
Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
www.limcr.at and
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
www.cccit.at

in cooperation with the
Cancer Cluster Salzburg | www.cancercluster-salzburg.at and **AGMT gemeinnützige GmbH** | www.agmt.at



Salzburg
Cancer
Research
Institute

CCCIT
Center for
Clinical Cancer
and Immunology Trials

LIMCR
Laboratory for
Immunological and
Molecular Cancer Research



CANCER
CLUSTER
SALZBURG
WWW.CANCERCLUSTER-SALZBURG.AT

AGMT

ARBEITSGEMEINSCHAFT
MEDIKAMENTÖSE
TUMORTHERAPIE

Kindly supported by: AstraZeneca



NOVARTIS
ONCOLOGY



Bristol-Myers Squibb

This event will be requested for
12 DFP points